HPV16 RG1 VLP vaccine

A monovalent chimeric human papillomavirus (HPV) virus-like particles (VLPs)-based vaccine containing the epitope RG1, which is comprised of amino acids 17-36 of the minor capsid protein (L2) of HPV type 16 (HPV16), which is incorporated, in a repetitive and close manner, into the DE surface loop of the HPV16 major capsid protein (L1) VLP backbone (HPV16 L1-VLP), that can potentially be used for active immunization against various types of HPV. Upon administration, the HPV16 RG1 VLP vaccine activates the immune system to produce neutralizing antibodies against HPV16 and various other HPV subtypes. This protects against HPV infection and HPV-related cancers.